These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 31863513

  • 1. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
    Ahlstrand E, Samuelsson J, Lindgren M, Pettersson H, Liljeholm M, Ravn-Landtblom A, Scheding S, Andréasson B.
    Eur J Haematol; 2020 Mar; 104(3):271-278. PubMed ID: 31863513
    [Abstract] [Full Text] [Related]

  • 2. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.
    Abdulkarim K, Samuelsson J, Johansson P, Andréasson B.
    Eur J Haematol; 2017 Jun; 98(6):577-583. PubMed ID: 28251679
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML, Fabris F, Ruzzon E, Pacquola E, Cella G, Girolami A.
    Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
    [Abstract] [Full Text] [Related]

  • 10. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
    Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber RM, Verstovsek S.
    Leuk Res; 2022 Apr; 115():106809. PubMed ID: 35220060
    [Abstract] [Full Text] [Related]

  • 11. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.
    Pósfai É, Marton I, Borbényi Z, Nemes A.
    Anatol J Cardiol; 2016 Jun; 16(6):397-402. PubMed ID: 27182615
    [Abstract] [Full Text] [Related]

  • 12. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.
    Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH.
    Eur J Haematol; 2013 Mar; 90(3):228-36. PubMed ID: 23281576
    [Abstract] [Full Text] [Related]

  • 13. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
    Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M.
    Am J Med; 2004 Nov 15; 117(10):755-61. PubMed ID: 15541325
    [Abstract] [Full Text] [Related]

  • 14. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
    Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F.
    Ann Intern Med; 2003 Sep 16; 139(6):470-5. PubMed ID: 13679323
    [Abstract] [Full Text] [Related]

  • 15. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 16. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N.
    Ann Hematol; 2018 Jan 20; 97(1):109-121. PubMed ID: 29143068
    [Abstract] [Full Text] [Related]

  • 17. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
    Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M.
    Blood; 2008 Sep 15; 112(6):2199-204. PubMed ID: 18451307
    [Abstract] [Full Text] [Related]

  • 18. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.
    Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, Zhou L, Verstovsek S.
    Leuk Res; 2013 Nov 15; 37(11):1472-6. PubMed ID: 23993426
    [Abstract] [Full Text] [Related]

  • 19. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey.
    Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Micò C, Vannucchi AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A, Mazzucconi MG, Santoro C, Barbui T, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Chronic Myeloproliferative Diseases Working Party.
    Blood; 2008 Jan 15; 111(2):666-71. PubMed ID: 17909074
    [Abstract] [Full Text] [Related]

  • 20. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
    Alvarez-Larrán A, Pereira A, Magaz M, Hernández-Boluda JC, Garrote M, Cuevas B, Ferrer-Marín F, Gómez-Casares MT, García-Gutiérrez V, Mata-Vázquez MI, Turon F, Hernandez-Gea V, Arellano-Rodrigo E, Cervantes F, García-Pagán JC, GEMFIN and REHEVASC groups.
    Ann Hematol; 2020 Apr 15; 99(4):791-798. PubMed ID: 32086587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.